BSE filing, NSE: VANTA. Summary written from the filing by ALFA Finder's alert engine.
Vanta Bioscience Ltd: key numbers
- Share price
- ₹20.40
- Market cap
- ₹14.51 Cr
- Revenue (annual)
- ₹1.82 Cr
- Net profit (annual)
- ₹0.11 Cr
- P/E (TTM)
- 134.0×Sector 34.0×
- Promoter holding
- 72.81%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vanta Bioscience Ltd
All →Vanta Bioscience Annual General Meeting
Vanta Bioscience Ltd has issued notice for its upcoming Annual General Meeting scheduled for September 30, 2026, to transact key business resolutions.
Vanta Bioscience Annual Report
Vanta Bioscience Ltd submitted its Annual Report and AGM notice for FY 2025-26. The 10th AGM is scheduled for September 30, 2026.
Vanta Bioscience Annual General Meeting
Vanta Bioscience approved the Annual Report for FY 2025-26 and scheduled the 10th Annual General Meeting for September 30, 2026.
Vanta Bioscience H2 FY26 Results: Turns Profitable, Net Profit ₹1.9 Cr
Vanta Bioscience Ltd reported revenue from operations of ₹1.5 Cr (+400.0% YoY) and net profit of ₹1.9 Cr for H2 FY26.
- Key figure
- Net profit ₹1.9 Cr
Vanta Bioscience Financial Results
Vanta Bioscience Limited approved audited standalone and consolidated financial results for FY2026. The board also re-appointed Mr. Dopesh Raja Mulakala as Managing Director for three years.
Vanta Bioscience Board Meeting Date
Vanta Bioscience scheduled a board meeting on May 30, 2026, to approve fiscal 2026 financial results. The trading window remains closed until June 1, 2026.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.